Utilizing the host immune system to eradicate cancer cells has been the most investigated subject in the cancer research field in recent years. However, most of the studies have focused on highly variable responses from immunotherapies such as immune checkpoint inhibitors, from which the majority of patients experienced no or minimum clinical benefit. Advances in genomic sequencing technologies have improved our understanding of immunopharmacogenomics and allowed us to identify novel cancer-specific immune targets. Highly tumor-specific antigens, neoanti- 
to anti-PD-1 therapy. 4 Contrarily, it has been shown in several studies that patients who lacked the PD-L1 expression in cancer tissues
showed clinical benefit from anti-PD-1 therapy. 5 Another PD-1 ligand, PD-L2, is also known to suppress cytotoxic activity of T cells in tumors; thereby high PD-L2 expression could be associated with treatment response. 6 Several studies have investigated predictive biomarkers for response to immune checkpoint antibodies. 7 We previously reported that the expression levels of granzyme A and human leukocyte antigen (HLA)-A in melanoma tissues before treated with anti-PD-1 antibody were significantly higher in responders compared to non-responders, 8 which could indicate their value as potential biomarkers to predict clinical responses. Recent reports suggest that loss of heterozygosity of HLA class I locus is an immune escape mechanism that is related with poor outcome in patients who received immune checkpoint inhibitor therapy. 9,10 Furthermore, we showed that the T-cell receptor (TCR) repertoire of tumor-infiltrated T cells might be useful information for the evaluation or assessment of the immune microenvironment. 8 Recent reports, including ours, suggested that durable response to immune checkpoint blockade correlated with early and sustained expansion of a few dominant T-cell clones in peripheral blood, and that TCR sequencing can be used to detect early signs of response/resistance to immune checkpoint blockade. 11, 12 A series of studies have also addressed the relationship between mutational burden and immunotherapeutic outcome. Early studies supported the hypothesis that the extent of DNA damage is correlated with therapeutic response in melanoma patients treated with anti-CTLA-4 antibody, 13 and non-small-cell lung cancer patients treated with anti-PD1 antibody. 14 A more recent study also found the predictive power for neoantigen load in anti-CTLA-4-treated melanoma patients. 15 More importantly, mismatch-repair proficiency was associated with clinical response; it was observed that patients who have a higher number of somatic mutations due to the mismatchrepair deficiency were more susceptible to PD-1 blockade therapy compared to patients without the mismatch-repair deficiency. 16 The results from these studies all indicated a strong positive relationship between the numbers of predicted neoantigens, host immunological responses, and overall survival. A high somatic mutation burden should theoretically increase the probability of generating neoanti- Interestingly, these studies found that tumors with 150-200 nonsynonymous somatic mutations showed an elevated cytolytic T cell score. Several other studies supported that higher predicted neoantigen load was also associated with lymphocytic infiltration into tumors and survival rate. These associations were observed across both microsatellite stable and unstable tumors in colorectal and ovarian cancer patients. 22, 23 In 2014, we also reported similar findings on the association between somatic mutations and survival rate KIYOTANI ET AL.
| 543 using whole-exome and target sequencing in 78 muscle-invasive bladder cancer patients. We found that carriers of somatic mutations in DNA repair genes had significantly better recurrence-free survival compared with non-carriers (median, 32.4 vs 14.8 months; hazard ratio, 0.46; P = .044). 24 The follow-up study identified that tumors with higher neoantigen load showed lower TCR diversity, which correlated with oligoclonal tumor-infiltrating T lymphocyte expansion, and showed a significant association with longer recurrence-free survival (hazard ratio, 0.37; P = .033). 25 We also described the correlation between higher neoantigen load and T-cell activation among different portions within the same tumors.
26,27

| NEOANTIGEN PRED ICTION
It is still a major challenge to accurately predict the interaction between neoantigens and immune cells. There are currently several publicly available neoantigen prediction pipelines, including pVACSeq, 28 INTEGRATE-neo, 29 TSNAD. 30 pVAC-Seq combines the tumor mutation and expression data to predict neoantigens by invoking 
| Human leukocyte antigen typing based on whole-exome data
In-depth understanding of HLA molecules is vital for accurate neoantigen prediction. The HLA class I molecules are critical mediators of the cytotoxic T-cell responses as they present antigen peptides on the cell surface to be recognized by TCR on T cells. The HLA gene cluster, located on the short arm of chromosome 6, is among the most polymorphic regions in the human genome, with thousands of documented alleles. 31 The HLA allele has a unique nomenclature that comprises the gene name indicating the locus (i.e.
A, B, or C) followed by successive sets of digits separated by colons. 32 The first two digits (field 1) specify the allele groups by serological activity (allele level resolution, ex. A*01 or A*02), and the second field indicates the protein sequence (protein level resolution, ex. A*02:01 or A*02:02). The remaining two sets distinguish synonymous polymorphisms and non-coding variations. At least 2-field HLA typing is required to accurately predict neoepitopes, which can bind to HLA molecules. Several tools have been developed to obtain HLA allele information from genome-wide sequencing data (whole-exome, whole-genome, and RNA sequencing data), including OptiType, 33 Polysolver, 34 PHLAT, 35 HLAreporter, 36 HLAforest, 37 HLAminer, 38 and seq2HLA. 39 We have tested 961 whole-exome data from the 1000 Genomes Project to evaluate the accuracy of these programs.
Among these algorithms, OptiType showed the highest accuracy of 97.2% for HLA class I alleles at the second field level, followed by 94.0% in Polysolver and 85.6% in PHLAT. An example of such an approach is NetMHC, 43, 44 which is one of the most commonly used and best validated prediction programs. These algorithms are trained using large datasets of peptide ligands such as those collected in the IEDB database; Recently, several methodologies were developed to interrogate patient's cellular immunity. These T cell-based functional assays use either in silico predicted short peptides or tandem minigenes. 50 As summarized in Table 1 , there are several reports in which neoantigen-specific T cells were successfully induced. We also developed a rapid pipeline to identify TCRs recognizing neoantigens. 51 The pro- 
| Immunopeptidome analysis
Due to the complexity of neoantigen prediction, often only a small fraction of the predicted neoantigens can be confirmed to be associated with neoantigen-driven immune responses. One of the approaches to further narrow down the selected candidates is to assess whether the predicted peptides in fact bind to the HLA molecules using liquid chromatography and tandem mass spectrometry (LC-MS/MS) analysis. 53 The best-established strategy to isolate peptides on the HLA is immunoaffinity purification of HLA-peptide complexes using pan-anti-HLA class I or class II antibodies. Typically, including ones reported by our group. [61] [62] [63] As previously mentioned, neoantigens are immunogenic non-self-peptides that are generated by somatic mutations in cancer cells; therefore, they have attracted much attention as cancer cell-specific antigens. 64 Neoantigen-specific T cells have already shown positive clinical results. 65, 66 Recently, the results of 2 phase I clinical trials were reported that assessed a personalized neoantigen vaccine approach to treat patients with melanoma. 67, 68 Both studies found that the vaccine treatment induced neoantigen-specific CD4 + and CD8 + T cells, and indicated potential benefits of neoantigen-based vaccines.
Ott et al. 67 showed that 4 of 6 vaccinated patients had no recurrence at 25 months after the vaccination, and 2 patients with recurrent disease had complete regression by subsequent treatment with anti-PD-1 antibodies. Sahin et al. 68 showed that 8 of 13 vaccinated patients mounted strong immune responses and remained recurrence-free for 12-23 months. Two of the remaining 5 patients with metastatic disease experienced vaccine-related objective responses.
These results indicate that neoantigen vaccines can be a promising treatment option to induce neoantigen-specific T cells in cancer patients.
T A B L E 1 Summary of studies identifying neoantigen-specific T cells However, the key rate-limiting factor for the progress of neoantigenspecific T-cell therapy is the insufficient accuracy of neoantigen prediction, including the HLA-binding affinity, the immunogenicity of predicted peptides in individual cancer patients, and also the crossreactivity to WT peptides. Further studies are required to establish precise neoantigen prediction with efficient validity assays. In addition, accurate prediction in selecting the patient groups that may benefit from neoantigen-targeted immunotherapies will further reduce the likelihood of unwanted adverse effects.
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